You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 12, 2024

Investigational Drug Information for Chiauranib


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Chiauranib?

Chiauranib is an investigational drug.

There have been 16 clinical trials for Chiauranib. The most recent clinical trial was a Phase 2 trial, which was initiated on March 5th 2021.

The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Chipscreen Biosciences, Ltd., Medelis Inc., and H & J CRO International, Inc.

There is one US patent protecting this investigational drug.

Recent Clinical Trials for Chiauranib
TitleSponsorPhase
Anti-PD-1 and CTLA-4 Bispecific Antibody AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung CancerChipscreen Biosciences, Ltd.Phase 1/Phase 2
Anti-PD-1 and CTLA-4 Bispecific Antibody AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung CancerAkesoPhase 1/Phase 2
Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)Chipscreen Biosciences, Ltd.Phase 2

See all Chiauranib clinical trials

Clinical Trial Summary for Chiauranib

Top disease conditions for Chiauranib
Top clinical trial sponsors for Chiauranib

See all Chiauranib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.